Suping Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suping Fan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Binbin Xue
Institute of Pathogen Biology and Immunology, Department of Pharmacy, College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha, China
1 shared publication - Changping Yu
Institute of Pathogen Biology and Immunology, Department of Pharmacy, College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha, China
1 shared publication Chaohui Zuo
Department of Gastroduodenal and Pancreatic Surgery, Translational Medicine Research Center of Liver Cancer, Hunan Cancer Hospital, Changsha, China
1 shared publication- Cong Wang
Institute of Pathogen Biology and Immunology, Department of Pharmacy, College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha, China
1 shared publication - Haizhen Zhu
Institute of Pathogen Biology and Immunology, College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China
1 shared publication - Hui Liu
Institute of Pathogen Biology and Immunology, Department of Pharmacy, College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 16 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
RasGRP1 promotes the acute inflammatory response and restricts inflammation-associated cancer cell growth
An acute inflammatory response needs to be properly regulated to promote the elimination of pathogens and prevent the risk of tumorigenesis, but the relevant regulatory mechanism has not been fully elucidated. Here, we report that Ras guanine nucleotide-releasing protein 1 (RasGRP1) is a bifunctional regulator that promotes acute inflammation and inhibits inflammation-associated cancer. At the mRNA level, Rasgrp1 activates the inflammatory response by functioning as a competing endogenous RNA to specifically promote IL-6 expression by sponging let-7a. In vivo overexpression of the Rasgrp1 3’ untranslated region enhances lipopolysaccharide-induced systemic inflammation and dextran sulphate sodium-induced colitis in Il6+/+ mice but not in Il6-/- mice. At the protein level, RasGRP1 overexpression significantly inhibits the tumour-promoting effect of IL-6 in hepatocellular carcinoma progenitor cell-like spheroids. Examination of the EGFR signalling pathway shows that RasGRP1 inhibits inflammation-associated cancer cell growth by disrupting the EGFR-SOS1-Ras-AKT signalling pathway. Tumour patients with high RasGRP1 expression have better clinical outcomes than those with low RasGRP1 expression. Considering that acute inflammation rarely leads to tumorigenesis, this study suggests that RasGRP1 may be an important bifunctional regulator of the acute inflammatory response and tumour growth.
- 16 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessRasGRP1 promotes the acute inflammatory response and restricts inflammation-associated cancer cell growth
An acute inflammatory response needs to be properly regulated to promote the elimination of pathogens and prevent the risk of tumorigenesis, but the relevant regulatory mechanism has not been fully elucidated. Here, we report that Ras guanine nucleotide-releasing protein 1 (RasGRP1) is a bifunctional regulator that promotes acute inflammation and inhibits inflammation-associated cancer. At the mRNA level, Rasgrp1 activates the inflammatory response by functioning as a competing endogenous RNA to specifically promote IL-6 expression by sponging let-7a. In vivo overexpression of the Rasgrp1 3’ untranslated region enhances lipopolysaccharide-induced systemic inflammation and dextran sulphate sodium-induced colitis in Il6+/+ mice but not in Il6-/- mice. At the protein level, RasGRP1 overexpression significantly inhibits the tumour-promoting effect of IL-6 in hepatocellular carcinoma progenitor cell-like spheroids. Examination of the EGFR signalling pathway shows that RasGRP1 inhibits inflammation-associated cancer cell growth by disrupting the EGFR-SOS1-Ras-AKT signalling pathway. Tumour patients with high RasGRP1 expression have better clinical outcomes than those with low RasGRP1 expression. Considering that acute inflammation rarely leads to tumorigenesis, this study suggests that RasGRP1 may be an important bifunctional regulator of the acute inflammatory response and tumour growth.